SESSION TITLE: Bronchiectasis
SESSION TYPE: Slide Presentations
PRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AM
PURPOSE: To discuss the prevalence, risk factors and clinical features of bronchiectasis with NTM lung disease (NTMLD)
METHODS: Retrospective analysis of the information of patients diagnosed as bronchiectasis or bronchiectasis with NTMLD from January 2009 to December 2012 in the electronic databases of the hospital. The demographic data, risk factors and clinical characteristics data were concluded and comparatively analyzed. Systematic analysis was performed in 192 cases who diagnosed as bronchiectasis with NTMLD.
RESULTS: The number of eligible patients with bronchiectasis was 3,857 cases. 431 cases of bronchiectasis had at least one positive culture result of NTM, the separation rate was 11.2%. Patients with ultimate diagnosis of bronchiectasis with NTMLD were 192 cases, accounting for 4.98%. The sex ratio of bronchiectasis with NTMLD group was 1:2.1. They were mostly from the southern provinces. The percentages of past history of pulmonary tuberculosis in bronchiectasis patients with or without NTMLD were significantly different (16.7% vs. 28.8%). The proportion of history of long-term use of immunosuppressive agents in bronchiectasis with NTMLD patients (11.5%) was significantly higher than that in bronchiectasis patients (5%). There are no differences in two groups on age, smoking history and history of diabetes. 24.3% of the bronchiectasis with NTMLD patients showed CD4 + T/CD8 + T cell ratio decreased. The positive rates of blood tuberculosis antibody test and blood interferon gamma release assay (IGRA/T-SPOT) test in bronchiectasis with NTMLD patients were low. The PPD skin test results mainly showed a diameter of less than 10mm. The separation rate of other bacteria in bronchiectasis with NTMLD (14.1%) was lower than that in bronchiectasis patients (24.5%). The CT-scan of bronchiectasis with NTMLD showed lung lesions mainly in the above lung fields, with dominant of thin-walled small cavities, small nodules or fiber cord.
CONCLUSIONS: 4.98% of bronchiectasis patients combined with NTMLD in China. Women, residents of southern and long-term use of immunosuppressive agents in bronchiectasis patients were prone to accompany NTMLD.
CLINICAL IMPLICATIONS: For susceptible bronchiectasis patients, doctors should take the initiative to screen whether combining NTMLD.
DISCLOSURE: The following authors have nothing to disclose: Jin-Fu Xu, Heping Xiao
No Product/Research Disclosure Information